Cargando…
Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents
We report the results of an independent laboratory’s tests of novel agents to prevent or reverse type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse, BioBreeding diabetes prone (BBDP) rat, and multiple autoimmune disease prone (MAD) rat models. Methods were developed to better mimic human cl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758263/ https://www.ncbi.nlm.nih.gov/pubmed/24023664 http://dx.doi.org/10.1371/journal.pone.0072989 |
_version_ | 1782282326429925376 |
---|---|
author | Grant, Christian W. Moran-Paul, Catherine M. Duclos, Shane K. Guberski, Dennis L. Arreaza-Rubín, Guillermo Spain, Lisa M. |
author_facet | Grant, Christian W. Moran-Paul, Catherine M. Duclos, Shane K. Guberski, Dennis L. Arreaza-Rubín, Guillermo Spain, Lisa M. |
author_sort | Grant, Christian W. |
collection | PubMed |
description | We report the results of an independent laboratory’s tests of novel agents to prevent or reverse type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse, BioBreeding diabetes prone (BBDP) rat, and multiple autoimmune disease prone (MAD) rat models. Methods were developed to better mimic human clinical trials, including: prescreening, randomization, blinding, and improved glycemic care of the animals. Agents were suggested by the research community in an open call for proposals, and selected for testing by an NIDDK appointed independent review panel. Agents selected for testing to prevent diabetes at later stages of progression in a rodent model were a STAT4 antagonist (DT22669), alpha(1) anti-trypsin (Aralast NP), celastrol (a natural product with anti-inflammatory properties), and a Macrophage Inflammatory Factor inhibitor (ISO-092). Agents tested for reversal of established T1D in rodent models were: alpha(1) anti-trypsin (Aralast NP), tolerogenic peptides (Tregitopes), and a long-acting formulation of GLP-1 (PGC-GLP-1). None of these agents were seen to prevent or reverse type 1 diabetes, while the positive control interventions were effective: anti-CD3 treatment provided disease reversal in the NOD mouse, dexamethasone prevented T1D induction in the MAD rat, and cyclosporin prevented T1D in the BBDP rat. For some tested agents, details of previous formulation, delivery, or dosing, as well as laboratory procedure, availability of reagents and experimental design, could have impacted our ability to confirm prior reports of efficacy in preclinical animal models. In addition, the testing protocols utilized here provided detection of effects in a range commonly used in placebo controlled clinical trials (for example, 50% effect size), and thus may have been underpowered to observe more limited effects. That said, we believe the results compiled here, showing good control and repeatability, confirm the feasibility of screening diverse test agents in an independent laboratory. |
format | Online Article Text |
id | pubmed-3758263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37582632013-09-10 Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents Grant, Christian W. Moran-Paul, Catherine M. Duclos, Shane K. Guberski, Dennis L. Arreaza-Rubín, Guillermo Spain, Lisa M. PLoS One Research Article We report the results of an independent laboratory’s tests of novel agents to prevent or reverse type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse, BioBreeding diabetes prone (BBDP) rat, and multiple autoimmune disease prone (MAD) rat models. Methods were developed to better mimic human clinical trials, including: prescreening, randomization, blinding, and improved glycemic care of the animals. Agents were suggested by the research community in an open call for proposals, and selected for testing by an NIDDK appointed independent review panel. Agents selected for testing to prevent diabetes at later stages of progression in a rodent model were a STAT4 antagonist (DT22669), alpha(1) anti-trypsin (Aralast NP), celastrol (a natural product with anti-inflammatory properties), and a Macrophage Inflammatory Factor inhibitor (ISO-092). Agents tested for reversal of established T1D in rodent models were: alpha(1) anti-trypsin (Aralast NP), tolerogenic peptides (Tregitopes), and a long-acting formulation of GLP-1 (PGC-GLP-1). None of these agents were seen to prevent or reverse type 1 diabetes, while the positive control interventions were effective: anti-CD3 treatment provided disease reversal in the NOD mouse, dexamethasone prevented T1D induction in the MAD rat, and cyclosporin prevented T1D in the BBDP rat. For some tested agents, details of previous formulation, delivery, or dosing, as well as laboratory procedure, availability of reagents and experimental design, could have impacted our ability to confirm prior reports of efficacy in preclinical animal models. In addition, the testing protocols utilized here provided detection of effects in a range commonly used in placebo controlled clinical trials (for example, 50% effect size), and thus may have been underpowered to observe more limited effects. That said, we believe the results compiled here, showing good control and repeatability, confirm the feasibility of screening diverse test agents in an independent laboratory. Public Library of Science 2013-08-30 /pmc/articles/PMC3758263/ /pubmed/24023664 http://dx.doi.org/10.1371/journal.pone.0072989 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Grant, Christian W. Moran-Paul, Catherine M. Duclos, Shane K. Guberski, Dennis L. Arreaza-Rubín, Guillermo Spain, Lisa M. Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title | Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title_full | Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title_fullStr | Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title_full_unstemmed | Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title_short | Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents |
title_sort | testing agents for prevention or reversal of type 1 diabetes in rodents |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758263/ https://www.ncbi.nlm.nih.gov/pubmed/24023664 http://dx.doi.org/10.1371/journal.pone.0072989 |
work_keys_str_mv | AT grantchristianw testingagentsforpreventionorreversaloftype1diabetesinrodents AT moranpaulcatherinem testingagentsforpreventionorreversaloftype1diabetesinrodents AT duclosshanek testingagentsforpreventionorreversaloftype1diabetesinrodents AT guberskidennisl testingagentsforpreventionorreversaloftype1diabetesinrodents AT arreazarubinguillermo testingagentsforpreventionorreversaloftype1diabetesinrodents AT spainlisam testingagentsforpreventionorreversaloftype1diabetesinrodents |